Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
We here report a series of derivatives describing the structure-activity relationship around liraglutide, a once-daily human glucagon-like peptide-1 fatty acid derivative, with respect to potency as well as protraction in vivo. The spacer region between the fatty acid and the peptide is mostly important for potency, whereas the fatty acid or fatty acid mimetic is important for both potency and protraction. The length of the fatty acid is the most important parameter for protraction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LIR is suitable to be administered once a day, with a tmax of 9~13 hours and t1/2 of 13 hours (80–82).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [82]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAugeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Research works printed but not linked: 9
- Kim D., 2005, J. Med. Chem., 48, 151
- Vilsboll T., 2003, J. Clin. Endocrinol. Metab., 88, 224
- Edwards C. M. B., 2001, Am. J. Physiol. Endocrinol. Metab., 281, E161
- Kim J. G., 2003, Diabetes, 52, 759
- Dong J. Z., 2003, Biopolymers, 71, 2003
- Chou J. Z., 1997, J. Pharm. Sci., 86, 773
- Youn Y. S., 2007, Biochem. Pharmacol., 73, 93
- Degn K. B., 2004, Diabetes, 53, 1194
- DeFronzo R. A., 2005, Diabetes Care, 28, 1100
Cited by
Items 201–260 of 260
Discovery of a Long-Acting Parathyroid Hormone 1–34 Analogue to Treat Hypoparathyroidism
Ruan, S., Gui-ying, Y., Dong, Y., Shangguan, W., & Lu, W. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00149 · Cited by 4
Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists
Zhang, X., Cai, Y., Yao, Z., Chi, H., Li, Y., Shi, J., Zhou, Z., & Sun, L. (2023) · Peptides · doi:10.1016/j.peptides.2023.170948 · Cited by 6
Functional screening system for yeast-secreted peptides acting on G-protein coupled receptors
Shigemori, T., Kuroda, K., & Ueda, M. (2015) · AMB Express · doi:10.1186/s13568-015-0113-8 · Cited by 3
“Whereas the N-terminal two residues (His-Ala) in GLP1 are reported to be critical for its biological activity, the C-terminal part is tolerable to various modifications such as fatty acid conjugation or albumin fusion (Baggio et al. 2004; Madsen et al. 2007).”
BackgroundA New Protractor Potentiates Glucagon-Like Peptide 1 with Slow-Release Depot and Long-Term Action
Jing, W., Peng, L., Song, S., Liu, J., & Tai, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02970 · Cited by 3
Revell, J. D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821061-1.00003-4 · Cited by 3
Zaykov, A. N., Gelfanov, V. M., Tagmose, T. M., Demozay, D., Manfé, V., Rohlfs, R., Rivir, M., Pérez–Tilve, D., Finan, B., & DiMarchi, R. D. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00078a · Cited by 4
Engineered Neuromedin U Promotes Type 2 Innate Immunity and Renoprotection in Acute Kidney Injury
Trindade-Correia, S., Correia, V., Delgado, F. J., Baptista, M., Cabral, I. A., Carvalho, T., Macedo, L., Nunes, M., Andrade, P. Z., Cardoso, F., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000747 · Cited by 3
Structural Aspects of Gut Peptides with Therapeutic Potential for Type 2 Diabetes
Hewage, C. M., & Venneti, K. C. (2013) · ChemMedChem · doi:10.1002/cmdc.201200445 · Cited by 3
Steenkamp, L. H., & Steenkamp, P. A. (2025) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2025.2502034 · Cited by 2
Cysteinylprolyl ester-mediated drug release from a lipid–drug conjugate
Tsuji, T., Inazuki, H., Kobayashi, D., Hayashi, J., Denda, M., & Otaka, A. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129850 · Cited by 2
Treating Type 2 Diabetes Mellitus
Herzlinger, S., & Abrahamson, M. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_44 · Cited by 4
Liraglutide, a GLP‐1 Analogue to Treat Diabetes
Knudsen, L. B. (2010) · Wiley eBooks · doi:10.1002/9783527630035.ch14 · Cited by 2
Self-citationSynthesis of a Novel PTH1–34 Analog with Increased Human Serum Albumin Affinity
Ruan, S., Dong, Y., Lu, J., Zhao, M., Lu, W., & Feng, J. (2021) · Pharmaceutical Fronts · doi:10.1055/s-0041-1731299 · Cited by 2
Kahal, H. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 2
AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES
Ismail, R., Anter, A. F., Matouk, A. I., & Heeba, G. H. (2022) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2022.160122.1493 · Cited by 2
Ligand Design with Accelerated Disulfide Formation with Serum Albumin to Extend Blood Retention
Qi, S., Liu, Z., Suyama, K., Tsuchiya, Y., Canarejo, J., Phan, K. Q., Yutsudo, N., Shimada, A., Hirota, T., Ieiri, I., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00503 · Cited by 1
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Gr, K., & Elrick, M. M. (2014) · Cited by 2
Zhu, J., Bai, L., Wang, C., Liu, J., Chen, Y., Zhang, W., Weng, J., Wei, L., & Wei, Z. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103505
“For example, the L-γ -glutamoyl (L-γ Glu) linker in zilucoplan (approved for generalized myasthenia gravis) and the butanoyl-sulfonamide linker in the long-acting human growth hormone somapacitan illustrate how tailored linker designs enhance pharmacokinetics and bioactivity [45 – 48].”
Hölscher, C. (2012) · Wiley eBooks · doi:10.1002/9781118185537.ch10 · Cited by 1
Hart, N. J. (2013) · UA Campus Repository (The University of Arizona)
Development of Single and Multimodality Imaging Probes for PET, SPECT and Fluorescence Imaging
Azad, B. B. (2011) · Scholarship@Western (Western University)
Hölscher, C. (2011) · InTech eBooks · doi:10.5772/18372
“The level of soluble amyloidoligomers was also greatly reduced (P. McClean et al. 2011). www.intechopen.com Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 680 Fig.”
InfluentialBioresponsive molecular imaging probes
Duijnhoven, V. S. S. (2012) · TU/e Research Portal · doi:10.6100/ir735301
GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator
Babateen, O. (2016) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 1
Molecular Imaging Agent Design for Quantifying Beta Cell Mass in Type 1 Diabetes
Zhang, L. (2017) · Deep Blue (University of Michigan) · Cited by 1
Position of lipidation influences anticancer activity of Smac analogs
Micewicz, E. D., Nguyen, C., Micewicz, A., Waring, A. J., McBride, W. H., & Ruchala, P. P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.041
The Effects of Lipidation on a TAT-Containing Peptide-Based Inhibitor of PSD-95
Fernandes, E. F. A., Haugaard‐Kedström, L. M., & Strømgaard, K. (2019) · Australian Journal of Chemistry · doi:10.1071/ch19392
Peptides in metabolic diseases
Demmer, O., Just, R., Rottländer, M., & Fosgerau, K. (2015) · doi:10.4155/fseb2013.14.49
Utilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Development of CGRP receptor peptide antagonists as potential therapeutics
Jamaluddin, A. (2020) · University of Birmingham Research Portal (University of Birmingham)
A brief review on newer Glucagon like Peptide-1 analogues
Dharmaraj, B. (2020) · International Journal of Preclinical and Clinical Research · doi:10.51131/ijpccr/v1i1.7
“(16,17) Manyof the pathophysiologic disturbances that are present”
BackgroundTreating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_44
Treating Type 2 Diabetes Mellitus
Migdal, A. L., Herzlinger, S., & Abrahamson, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-2
Treating Type 2 Diabetes Mellitus
Migdal, A. L., & Abrahamson, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_44-1
Liu, S. (2017) · Digital Repository Service (Northeastern University) · doi:10.17760/d20253330
nature inspired and medicinally relevant short peptides
Ciulla, M. G., Civera, M., & Sattin, S. (2023) · Vide Leaf, Hyderabad eBooks · doi:10.37247/updph2ed.2.23.4
Candeias, E. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Liao, Y., Hou, H., Xu, Y., & Li, J. (2026) · The Analyst · doi:10.1039/d6an00311g
Silverman, R. B., Xue, F., & Juncosa, J. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15862-9.00005-9
Martino, S. D., & Rosa, M. D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930768
“For example, in the design of liraglutide, the fatty acid length was fundamental to enhance the metabolic stability (Madsen et al., 2007).”
Alharbi, N. H. J. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70329
Lin, J., & Bratkowski, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.21.755545
BindingDB Entry 50006544: Small lipidated anti-obesity compounds derived from neuromedin U.
BindingDB (2020) · UC San Diego · doi:10.7270/q26h4mff
BindingDB (2012) · UC San Diego · doi:10.7270/q2vh5prk
BindingDB (2016) · UC San Diego · doi:10.7270/q2tx3h6d
BindingDB (2020) · UC San Diego · doi:10.7270/q2fn18tn
Su, R., Oykhman, L. P., & Wang, Y. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15011100/v1
Metadata
- Authors
- Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-11-01
- Volume
- 50
- Issue
- 24
- Pages
- 6126-6132
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1978143294
- Cited by
- 244
- References
- 26
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 12 · 2023: 10 · 2022: 13 · 2021: 17 · 2020: 16 · 2019: 12 · 2018: 22 · 2017: 21 · 2016: 18 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 9
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- liraglutide, structure-activity relationship, protraction, spacer region, drug potency, GLP-1 receptor agonists, steric bulkiness
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cyclic AMP, Amino Acid Sequence, Animals, Cell Line, Fatty Acids, Cricetinae, Humans, Molecular Sequence Data, Structure-Activity Relationship, Swine, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.